The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of August 9, 2018, the company operated approximately 400 clinics. The company was founded in 2010 and is headquartered in Scottsdale, Arizona.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Patent owners & lessors
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:JYNT
Previous Symbol
CUSIPN/A
Phone480-245-5960
Debt
Debt-to-Equity Ratio0.75
Current Ratio1.36
Quick Ratio1.30
Price-To-Earnings
Trailing P/E Ratio-32.12
Forward P/E Ratio133.83
P/E GrowthN/A
Sales & Book Value
Annual Sales$25.16 million
Price / Sales4.38
Cash FlowN/A
Price / CashN/A
Book Value$0.10 per share
Price / Book80.30
Profitability
EPS (Most Recent Fiscal Year)($0.25)
Net Income$-3,270,000.00
Net Margins-2.68%
Return on Equity-21.00%
Return on Assets-2.45%
Miscellaneous
Employees148
Outstanding Shares13,730,000
Market Cap$110.36 million
OptionableNot Optionable
Joint (NASDAQ:JYNT) Frequently Asked Questions
What is Joint's stock symbol?
Joint trades on the NASDAQ under the ticker symbol "JYNT."
How were Joint's earnings last quarter?
Joint Corp (NASDAQ:JYNT) announced its quarterly earnings results on Thursday, November, 8th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.02 by $0.01. The company earned $8.06 million during the quarter, compared to analyst estimates of $7.98 million. Joint had a negative net margin of 2.68% and a negative return on equity of 21.00%. View Joint's Earnings History.
When is Joint's next earnings date?
What guidance has Joint issued on next quarter's earnings?
Joint updated its FY 2018 earnings guidance on Thursday, November, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $31-32 million, compared to the consensus revenue estimate of $31.23 million.
What price target have analysts set for JYNT?
3 brokers have issued 1-year price objectives for Joint's stock. Their predictions range from $10.00 to $12.00. On average, they expect Joint's share price to reach $11.00 in the next year. This suggests a possible upside of 37.0% from the stock's current price. View Analyst Price Targets for Joint.
What is the consensus analysts' recommendation for Joint?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Joint in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Joint.
What are Wall Street analysts saying about Joint stock?
Here are some recent quotes from research analysts about Joint stock:
- 1. According to Zacks Investment Research, "The Joint Corp. is a healthcare franchisor of chiropractic clinics. The Company's plans include: Single Visit, Premium Wellness Plan and Wellness Plan. It also provides a family wellness plan. The Company also provides removal of subluxations. It operates its clinics across: Albany, New York; Austin, Texas; Brentwood, California; Fort Mill, South Carolina; Lubbock, Texas; Lynnwood, Washington; Middletown, New Jersey; San Antonio, Texas; San Diego, California and Spartanburg, South Carolina, among others. The Joint Corp. is headquartered in Scottsdale, Arizona. " (10/11/2018)
- 2. Maxim Group analysts commented, "1Q18 revenue of $7.10M, up 28.9% y/y, was relatively inline with both our estimate of $7.18M and consensus of $7.06M.." (5/11/2018)
Has Joint been receiving favorable news coverage?
Media stories about JYNT stock have trended negative on Wednesday, InfoTrie reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Joint earned a news impact score of -2.1 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 9.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future.
Who are some of Joint's key competitors?
Some companies that are related to Joint include Acacia Research (ACTG), Quarterhill (QTRH), Liberty Tax (TAXA), Digital Turbine (APPS), Finjan (FNJN), XCel Brands (XELB), Research Frontiers (REFR), Marathon Patent Group (MARA), MGT Capital Investments (MGTI), ARC Group (ARCK), Spherix (SPEX), XpresSpa Group (XSPA), American Restaurant Partners LP Class A Partnership Units (ICTPU), Patriot Scientific (PTSC) and Health Discovery (HDVY).
Who are Joint's key executives?
Joint's management team includes the folowing people:
- Mr. Peter D. Holt, CEO, Pres, Interim Principal Financial Officer & Director (Age 59)
- Mr. Jorge Armenteros, VP of Operations
- Dr. James Edwards, Chief Chiropractic & Compliance Officer
- Mr. Craig P. Colmar, Sec. (Age 65)
- Jake Singleton, Corp. Controller
When did Joint IPO?
(JYNT) raised $20 million in an initial public offering (IPO) on Tuesday, November 11th 2014. The company issued 3,000,000 shares at a price of $6.50 per share. Roth Capital Partners and Feltl and Company acted as the underwriters for the IPO and Sanders Morris Harris was co-manager.
Who are Joint's major shareholders?
Joint's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Sanders Morris Harris LLC (10.42%), Renaissance Technologies LLC (1.55%), Russell Investments Group Ltd. (1.42%), Acadian Asset Management LLC (1.30%), Granite Investment Partners LLC (0.58%) and Perkins Capital Management Inc. (0.50%). Company insiders that own Joint stock include Bret Sanders, Glenhill Advisors Llc, James H Amos Jr, John P Meloun, Peter D Holt and Ronald V Davella. View Institutional Ownership Trends for Joint.
Which institutional investors are selling Joint stock?
JYNT stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Sanders Morris Harris LLC, Renaissance Technologies LLC, JPMorgan Chase & Co., JPMorgan Chase & Co. and Russell Investments Group Ltd.. Company insiders that have sold Joint company stock in the last year include John P Meloun and Ronald V Davella. View Insider Buying and Selling for Joint.
Which institutional investors are buying Joint stock?
JYNT stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Granite Investment Partners LLC, Perkins Capital Management Inc. and Advisory Services Network LLC. Company insiders that have bought Joint stock in the last two years include Bret Sanders, James H Amos Jr, John P Meloun and Peter D Holt. View Insider Buying and Selling for Joint.
How do I buy shares of Joint?
Shares of JYNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Joint's stock price today?
One share of JYNT stock can currently be purchased for approximately $8.03.
How big of a company is Joint?
Joint has a market capitalization of $110.36 million and generates $25.16 million in revenue each year. The company earns $-3,270,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Joint employs 148 workers across the globe.
What is Joint's official website?
How can I contact Joint?
Joint's mailing address is 16767 N PERIMETER DRIVE SUITE 240, SCOTTSDALE AZ, 85260. The company can be reached via phone at 480-245-5960 or via email at [email protected]
MarketBeat Community Rating for Joint (NASDAQ JYNT)
MarketBeat's community ratings are surveys of what our community members think about Joint and other stocks. Vote "Outperform" if you believe JYNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JYNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
